If you liked this article you might like

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too
AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment
AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers
Nasdaq Tumbles as Tech Takes a Turn Lower